Merck - 53 Year Stock Price History | MRK

Historical daily share price chart and data for Merck since 1970 adjusted for splits and dividends. The latest closing stock price for Merck as of November 28, 2023 is 100.18.
  • The all-time high Merck stock closing price was 116.80 on May 08, 2023.
  • The Merck 52-week high stock price is 119.65, which is 19.4% above the current share price.
  • The Merck 52-week low stock price is 96.36, which is 3.8% below the current share price.
  • The average Merck stock price for the last 52 weeks is 108.67.
For more information on how our historical price data is adjusted see the Stock Price Adjustment Guide.
Merck Historical Annual Stock Price Data
Year Average Stock Price Year Open Year High Year Low Year Close Annual % Change
2023 107.4274 108.9155 116.8023 100.1800 100.1800 -7.86%
2022 86.5816 73.0034 109.8759 69.8124 108.7293 49.38%
2021 72.0765 74.2028 85.1884 66.1464 72.7849 -2.92%
2020 72.8146 81.7698 81.7698 59.4597 74.9727 -7.21%
2019 71.9601 65.3795 81.5033 63.0701 80.8015 22.26%
2018 54.6142 47.1657 68.1330 45.0516 66.0887 40.00%
2017 51.2929 48.9559 55.0333 45.0015 47.2077 -1.47%
2016 46.0059 41.3778 52.4716 38.3107 47.9141 15.05%
2015 43.7787 43.6288 48.0840 37.8429 41.6458 -3.87%
2014 42.9169 36.6306 46.8514 36.6306 43.3236 16.95%
2013 33.6625 29.5003 37.0451 29.1506 37.0451 26.80%
2012 28.8142 26.2360 33.8927 25.5578 29.2148 13.13%
2011 22.7819 23.5762 25.9620 19.9393 25.8250 9.54%
2010 23.0194 23.2149 25.7365 20.1651 23.5762 2.86%
2009 18.0963 18.4428 23.8359 12.6924 22.9201 26.73%
2008 21.4567 32.6680 34.4787 13.8181 18.0858 -45.34%
2007 28.4205 24.3223 34.6040 23.7255 33.0893 37.36%
2006 20.7500 17.3859 25.3169 17.3859 24.0902 42.66%
2005 15.8294 15.7871 17.8527 13.5478 16.8869 4.04%
2004 20.7231 22.8837 23.8939 12.9531 16.2316 -27.76%
2003 24.5775 26.0815 28.6929 19.5806 22.4703 -11.35%
2002 23.8533 26.0887 28.2581 17.2520 25.3472 -1.26%
2001 30.6420 39.7086 39.7086 24.9580 25.6696 -35.79%
2000 31.2189 28.3817 40.4558 22.7460 39.9776 41.78%
1999 30.4747 30.9503 35.8170 25.3706 28.1971 -7.47%
1998 26.3987 21.8899 32.7892 20.9337 30.4751 41.32%
1997 19.0308 15.9542 21.8289 15.9542 21.5644 35.61%
1996 13.4347 12.5627 16.7425 11.2005 15.9022 23.92%
1995 9.5570 7.3154 13.0769 6.9570 12.8325 76.57%
1994 6.2301 6.4899 7.5060 5.2708 7.2677 14.82%
1993 6.3572 7.8416 7.8416 5.2055 6.3297 -18.35%
1992 8.5817 9.7186 9.8640 7.3101 7.7522 -20.29%
1991 6.9377 5.1273 9.7256 4.7119 9.7256 88.88%
1990 4.4670 4.3919 5.1490 3.7734 5.1490 18.95%
1989 3.8881 3.1217 4.4429 3.1217 4.3288 37.47%
1988 2.9445 2.9143 3.2229 2.5798 3.1489 12.05%
1987 2.9807 2.2340 3.8564 2.2340 2.8103 27.96%
1986 1.6951 1.2234 2.2961 1.2002 2.1963 80.84%
1985 0.9735 0.8256 1.2145 0.8012 1.2145 45.75%
1984 0.7856 0.8012 0.8599 0.7070 0.8333 4.01%
1983 0.8062 0.7447 0.9242 0.7269 0.8012 6.80%
1982 0.6815 0.7580 0.7779 0.5696 0.7502 -0.15%
1981 0.7706 0.7624 0.9076 0.6782 0.7513 0.00%
1980 0.6449 0.6272 0.7513 0.5208 0.7513 17.30%
1979 0.5986 0.6018 0.6549 0.5551 0.6405 6.84%
1978 0.5105 0.4754 0.6129 0.4267 0.5995 21.85%
1977 0.4978 0.5940 0.5940 0.4466 0.4920 -18.53%
1976 0.6340 0.6173 0.7126 0.5585 0.6039 -1.63%
1975 0.6602 0.5962 0.7580 0.5208 0.6139 4.32%
1974 0.6371 0.7126 0.7590 0.4344 0.5885 -17.80%
1973 0.7919 0.8023 0.8910 0.6893 0.7159 -9.39%
1972 0.6771 0.5552 0.7934 0.5552 0.7901 43.76%
1971 0.4699 0.4211 0.5796 0.4211 0.5496 25.25%
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $260.194B $59.283B
Merck & Co. boasts more than six blockbuster drugs in its portfolio with PD-L1 inhibitor, Keytruda, approved for several types of cancer. Keytruda has played an instrumental role in driving Merck's steady revenue growth in the past few years. Well-known products in Merck's portfolio include Keytruda, Simponi , Januvia and Janumet, Bridion, Isentress, ProQuad, Gardasil, Pneumovax 23, RotaTeq and Belsomra. Merck made its biggest acquisition of Schering-Plough and sold off its Consumer Care business to Bayer. Other key acquisitions include Idenix Pharmaceuticals, Cubist Pharmaceuticals, Rigontec, ArQule and Acceleron Pharma. IMerck spun off products from its Women's Health unit, legacy drugs and biosimilar products into a new publicly traded company called Organon & Co.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) United States $567.306B 100.95
Novo Nordisk (NVO) Denmark $464.863B 42.98
Johnson & Johnson (JNJ) United States $360.875B 14.29
AbbVie (ABBV) United States $244.191B 11.60
Novartis AG (NVS) Switzerland $201.892B 14.03
AstraZeneca (AZN) United Kingdom $197.738B 17.72
Pfizer (PFE) United States $169.279B 10.45
Sanofi (SNY) $117.623B 10.64
Innoviva (INVA) United States $0.873B 7.87